摘要
目的探讨免疫增强剂胸腺肽对慢性阻塞性肺病急性加重患者的疗效及免疫功能的影响。方法将诊断为COPD且处于急性加重的85例患者随机分为两组，其中治疗组42例，对照组43例，对照组给予抗感染、化痰、解痉等常规治疗，治疗组在对照组基础上加用胸腺肽，疗程为14天。观察：1．两组患者住院时间及6个月内急性发作次数的不同；2．治疗前后主要肺功能指标及免疫指标的变化。结果：1.胸腺肽能改善患者的临床症状，治疗组治疗后总有效率（92．86％）高于对照组（79．07％）（P〈0．05）：2．治疗组住院时间（9．57±3．36）及6个月内急性发作次数（1．25±1．12）均明显少于对照组，P〈0．05，P〈0．01；3．治疗组的主要肺功能指标FEVI．0、FVC、PEF均明显优于对照组，P〈0．05，P〈0．01；4．与治疗前比较，治疗组CD3＋、CD4＋显著高于对照组（P〈0．05或P〈0．01），而CD8＋无变化（P〉0．05）。结论用胸腺肽治疗AECOPD患者，可提高临床疗效，改善患者肺功能及免疫功能，减少急性发作次数，减少住院时间。
Objective To discuss the effect of thymosin on patients with chronic obstructive pulmonary disease （COPD）daring the period of acute exacerbation.Methods：85 patients with COPD during the period of acute exacerbation were ramdonly divided into two groups,there were 42 patients in treatment group,treated by thymosin in addition to routine treatment;there were 43 patients in control group,received anti-infective,resolving phlegm, antispasmodic,and so on routine treatment;The treatment course was 14 days;length of stay and the number of acute attack were observed in 6 months after treatment ;The major lung function and the immune index were measured.Results： 1.The marked improvement rate of treatment group （92.86%）was higher than that of control group （79.07%）,there was statistical difference （P〈0.05） ;2. The length of stay and the number of acute attack of treatment group were lower than those of control group,there was statistical difference （P〈0.01, 〈0.05）;3. The improvement of FEV 1.0,FVC,PEF in treatment group were superior to those in control group （P〈0.01,0.05）;4. The immune index CD3＋,CD4＋ were markedly higher than control group （P〈0.01, 〈0.05）.Conclusion：Thymosin could improve clinical symptoms of patients with AECOPD,and improve lung and immune function of patients,with the effects of reducing acute onset and length of stay.
出处
《世界中医药》
CAS
2016年第B06期2197-2198,共2页
World Chinese Medicine
关键词
慢性阻塞性肺疾病
急性加重期
胸腺肽
免疫功能
chronic obstructive pulmonary disease
acute exacerbation
thymosin
immune function
